Results 91 to 100 of about 44,269 (308)

A novel animal model to investigate fractionated radiotherapy-induced alimentary mucositis: the role of apoptosis, p53, nuclear factor-κB, COX-1, and COX-2 [PDF]

open access: bronze, 2007
Ann S. J. Yeoh   +6 more
openalex   +1 more source

Mucosal leishmaniasis [PDF]

open access: yesRevista da Sociedade Brasileira de Medicina Tropical, 2003
Lambertucci, José Roberto   +2 more
openaire   +4 more sources

Radiation therapy for amyloid‐producing odontogenic tumor in a cat: a case report

open access: yesAustralian Veterinary Journal, EarlyView.
Amyloid‐producing odontogenic tumor (APOT) is a rare odontogenic neoplasm in cats, characterized by amyloid deposition within the tumor. Surgical resection is commonly recommended, but in cases where complete excision is difficult, radiation therapy may be considered as an alternative treatment. In this case report, a 10‐year‐old male neutered domestic
A Uno, T Mori
wiley   +1 more source

Effect of Oral Zinc Sulphate in Preventionof Radiation Induced OropharyngealMucositis During and After Radiotherapyin Patients with Head and Neck Cancers

open access: yesMiddle East Journal of Cancer, 2010
Introduction:Mucositis is a disturbing side effect of radiotherapy treatment forhead and neck cancer. To date, no effective modality for its prophylaxis and treatmenthas been found. We performed this study to evaluate the efficacy of oral zincsulphate in
Mohammad Mohammadianpanah   +7 more
doaj  

Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA‐VEN) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia

open access: yesBritish Journal of Haematology, EarlyView.
Summary Induction chemotherapy in fit de novo acute myeloid leukaemia (AML) patients has historically combined an anthracycline with standard‐dose cytarabine (‘7 + 3’) despite complete response (CR) rates of 50%–70%. In May 2023, our institution adopted the utilization of cladribine, cytarabine, idarubicin and venetoclax (CLIA‐VEN) for intensive ...
Benjamin J. Lee   +11 more
wiley   +1 more source

Impact of Open Proximal Contacts on Peri-Implant Diseases: A Systematic Review and Meta-Analysis. [PDF]

open access: yesClin Exp Dent Res
ABSTRACT Objectives The aim of this systematic review and meta‐analysis was to evaluate the impact of open proximal contacts on peri‐implant tissue changes, specifically marginal bone levels, probing pocket depth, and the incidence of peri‐implant diseases.
Atieh MA   +5 more
europepmc   +2 more sources

Effectiveness and Safety of Radium‐223 for Bone‐Metastatic Castration‐Resistant Prostate Cancer: The KYUCOG‐1901 Study

open access: yesCancer Science, EarlyView.
The KYUCOG‐1901 prospective multicenter study evaluated radium‐223 in 93 Japanese patients with bone‐metastatic castration‐resistant prostate cancer. Ra‐223 was well tolerated, produced meaningful declines in ALP, and yielded a median overall survival of 23.0 months. Early initiation in patients with lower disease burden and integration with subsequent
Masaki Shiota   +12 more
wiley   +1 more source

Efficacy of Episil® in patients with hematologic malignancies: a comparative study

open access: yesBMC Oral Health
Background Episil® is a nonabsorbable liquid medical material used to coat and protect the mucosa in patients with oral mucositis. A few studies have reported its efficacy in patients with head and neck cancer.
Taeko Fukutani   +7 more
doaj   +1 more source

Surgical Outcomes Following Neoadjuvant‐Targeted Therapy for Advanced Differentiated Thyroid Cancer—Real‐World Data

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT Background Differentiated thyroid carcinoma (DTC) is typically managed surgically with favourable outcomes. However, surgery may have dire consequences when the tumour invades critical structures. Neoadjuvant therapy with tyrosine kinase inhibitors (TKIs) has emerged as a potential strategy to improve resectability and reduce morbidity in ...
Alexandra Dorman   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy